IN8bio Elevates Kate Rochlin to President and COO Amid Clinical Pipeline Expansion
Event summary
- Kate Rochlin, Ph.D., promoted to President and COO of IN8bio effective February 9, 2026.
- Rochlin previously served as COO since December 2021 and has been instrumental in advancing clinical programs like INB-619.
- INB-619 showed promising preclinical data for autoimmune disease treatment, achieving complete B cell depletion with minimal adverse effects.
- Rochlin's leadership spans operations, manufacturing, and regulatory affairs across multiple Phase 1 and 2 clinical trials.
The big picture
IN8bio's promotion of Kate Rochlin to President and COO underscores its focus on operational excellence as it scales its γδ T cell therapy pipeline. The move comes at a critical juncture, with promising preclinical data for INB-619 positioning the company for deeper regulatory engagement and potential clinical advancements. This strategic shift aligns with broader industry trends toward specialized T cell therapies for cancer and autoimmune diseases.
What we're watching
- Pipeline Momentum
- How IN8bio's clinical and preclinical pipeline advances under Rochlin's expanded leadership will impact its growth trajectory.
- Regulatory Strategy
- The pace at which INB-619 progresses toward clinical trials following promising preclinical results.
- Operational Scaling
- Whether Rochlin's leadership can sustain the company's manufacturing and regulatory capabilities amid expanding programs.
Our editorial coverage: